[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-355265-105":59,"doc-detail-355265-en":135},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":128,"head_meta":130,"extra_data":132,"updated_unix":134},105,"en","comparison-of-drug-regimens-for-recurrent-or-metastatic-cervical-cancer-a-systematic-review-and-network-meta-analysis","Comparison of drug regimens for recurrent or metastatic cervical cancer - a systematic review and network meta-analysis","","A systematic review and network meta-analysis compares drug regimens for patients with recurrent or metastatic cervical cancer (R/MCC) after surgery or radiotherapy. Using PRISMA-guided searches of PubMed, Web of Science, Embase, and the Cochrane Library for randomized controlled trials, overall survival (OS) served as the primary endpoint, with progression-free survival (PFS) as a secondary measure. Bayesian random-effects NMA plus SUCRA ranking, complemented by a frequentist sensitivity analysis, evaluated relative efficacy across chemotherapy, targeted therapy, and immunotherapy combinations.",{"@graph":69,"@context":127},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/comparison-of-drug-regimens-for-recurrent-or-metastatic-cervical-cancer-a-systematic-review-and-network-meta-analysis/355265/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/comparison-of-drug-regimens-for-recurrent-or-metastatic-cervical-cancer-a-systematic-review-and-network-meta-analysis/355265.png","ImageObject",300,407,{"name":92,"@type":93},"Aurelia","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",14,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119,123],{"name":110,"@type":111,"acceptedAnswer":112},"What population and setting does the review focus on?","Question",{"text":113,"@type":114},"Patients with recurrent or metastatic cervical cancer (R/MCC) after surgery or radiotherapy are the focus, where drug therapy is the primary treatment modality.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How were drug regimens compared in this study?",{"text":118,"@type":114},"The study used a systematic review and network meta-analysis of randomized controlled trials, applying Bayesian random-effects modeling with SUCRA ranking and a frequentist NMA as a sensitivity analysis.",{"name":120,"@type":111,"acceptedAnswer":121},"Which regimen showed the strongest overall survival benefit?",{"text":122,"@type":114},"Pembrolizumab plus chemotherapy and bevacizumab showed the greatest potential OS benefit, ranking first by SUCRA, compared with backbone chemotherapy.",{"name":124,"@type":111,"acceptedAnswer":125},"What was the conclusion about optimal treatment choice for R/MCC?",{"text":126,"@type":114},"Immune checkpoint inhibitor (ICI) combination regimens, with or without bevacizumab, are likely the optimal choice, while cisplatin plus paclitaxel remains the best backbone chemotherapy regimen.","https://schema.org",{"og:url":83,"og:type":129,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":131,"canonical":83},"index,follow",{"doc_id":133,"site_id":62},355265,1790172543,{"code":4,"msg":5,"data":136},{"doc_id":133,"user_id":137,"nickname":92,"user_avatar":138,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":139,"file_id":140,"file_url":141,"file_type":142,"file_size":143,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":144,"language":145,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":146,"faqs":147,"seo_title":148,"seo_description":67,"update_tm":149,"read_time":150,"preview_page_count":19,"preview_urls":151},1099514068365,"https://ap-avatar.wpscdn.com/avatar/10000253d8d9f28188e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1794309523707217728","TYPE Systematic Review PUBLISHED 25 February 2026  \nDOI 10.3389/fimmu.2026.1775409  \nOPEN ACCESS  \nEDITED BY  \nEmilie DeKrey,  \nUniversity of North Dakota, United States  \nREVIEWED BY  \nRicardo Cobucci,  \nFederal University of Rio Grande do Norte, Brazil  \nFang Li,  \nTongji University School of Medicine, China  \n*CORRESPONDENCE  \nLei Tian  \n [cputianlei@163.com](cputianlei@163.com)  \nRECEIVED 25 December 2025  \nREVISED 08 February 2026  \nACCEPTED 11 February 2026  \nPUBLISHED 25 February 2026  \nCITATION  \nZhou J, Ye W, Ranarisoa SN and Tian L (2026) Comparison of drug regimens for recurrent or metastatic cervical cancer: a systematic review and network meta-analysis.  \nFront. Immunol. 17:1775409 .  \ndoi: 10.3389/fimmu.2026.1775409  \nCOPYRIGHT  \n© 2026 Zhou, Ye, Ranarisoa and Tian. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) .  \nThe use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nComparison of drug regimens for recurrent or metastatic cervical cancer: a systematic review and network meta-analysis  \nJin Zhou, Wentao Ye, St´ephanie Nirina Ranarisoa and Lei Tian*  \nInternational Pharmaceutical Business School, China Pharmaceutical University, Nanjing, Jiangsu, China  \nBackground: Cervical cancer is one of the most common cancers among women worldwide. For patients with recurrent or metastatic cervical cancer (R/MCC) after surgery or radiotherapy, drug therapy is the primary treatment modality. Currently, head-to-head comparison studies of different immune checkpoint inhibitors (ICI) combination regimens are lacking in clinical practice. This study aims to provide an indirect comparison of the relative efﬁcacy of various drug regimens (including chemotherapy, targeted therapy, and immunotherapy) for R/ MCC patients through a systematic review and network meta-analysis (NMA) . Method: The study adhered to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guidelines and systematically searched databases including PubMed, Web of Science, Embase and the Cochrane Library for randomized controlled trials (RCTs) comparing drug treatment regimens. The primary efﬁcacy endpoint was overall survival (OS) . Progression-free survival (PFS) was analyzed as a secondary endpoint to provide additional evidence of clinical activity. We conducted the NMA using a Bayesian random-effects model, estimated the ranking of each treatment regimen via the Surface Under the Cumulative Ranking Curve (SUCRA), and performed a Frequentist NMA as a sensitivity analysis.  \nResult: A total of 15 RCTs involving 4,588 R/MCC patients were included. The NMA results for OS showed that ICI combination regimens (with or without bevacizumab) provided a signiﬁcant beneﬁt compared to backbone chemotherapy. Speciﬁcally, the regimen of pembrolizumab plus chemotherapy and bevacizumab showed the greatest potential for OS beneﬁt (Frequentist HR: 0.45, 95%CI: 0 .30–0. 67 vs. cisplatin plus paclitaxel), ranking ﬁrst by SUCRA (87%) . Among traditional chemotherapy regimens, only the cisplatin plus paclitaxel regimen was signiﬁcantly superior to single-agent cisplatin (Frequentist HR: 0. 74, 95%CI: 0 .59–0. 93) . The NMA results for PFS indicated that thecadonilima b plus chemotherapy regimen was the most outstanding (Frequentist HR: 0 .46, 95%CI: 0 .32–0. 66 vs. cisplatin plus paclitaxel), ranking ﬁrst by SUCRA (90%) . The rankings of the treatment regimens were consistent across both Bayesian and Frequentist, suggesting strong robustness of the results. Conclusion: ICI combination regimens (with or without bevacizumab) are likely the optimal choice for treating R/MCC patients. Pe mbrolizuma b plus","cbCaipIvye4T9pkH","https://ap.wps.com/l/cbCaipIvye4T9pkH","pdf",2486020,13,"English","# Background\n## Objective\n# Method\n## Study design and data sources\n## Endpoints and statistical approach\n# Result\n## Overall survival findings\n## Progression-free survival findings\n## Consistency across analyses\n# Conclusion\n## Clinical implications\n# Systematic Review Registration","[{\"question\":\"What population and setting does the review focus on?\",\"answer\":\"Patients with recurrent or metastatic cervical cancer (R/MCC) after surgery or radiotherapy are the focus, where drug therapy is the primary treatment modality.\"},{\"question\":\"How were drug regimens compared in this study?\",\"answer\":\"The study used a systematic review and network meta-analysis of randomized controlled trials, applying Bayesian random-effects modeling with SUCRA ranking and a frequentist NMA as a sensitivity analysis.\"},{\"question\":\"Which regimen showed the strongest overall survival benefit?\",\"answer\":\"Pembrolizumab plus chemotherapy and bevacizumab showed the greatest potential OS benefit, ranking first by SUCRA, compared with backbone chemotherapy.\"},{\"question\":\"What was the conclusion about optimal treatment choice for R/MCC?\",\"answer\":\"Immune checkpoint inhibitor (ICI) combination regimens, with or without bevacizumab, are likely the optimal choice, while cisplatin plus paclitaxel remains the best backbone chemotherapy regimen.\"}]","Comparison of drug regimens for recurrent or metastatic cervical cancer - a systematic review and network meta-analysis | PDF",1790117256,33,[152,156,160,164],{"page_no":8,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b9962e2a36ca77c668f15f3bb3d2c2e1.webp",983,1389,{"page_no":14,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2f9fadc5266e394f7f0672cd66964d04.webp",982,1388,{"page_no":81,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2eaadf4e7f6b6a11dd40911fc9107f00.webp",981,1386,{"page_no":19,"url":165,"width":166,"height":167},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dd34893f9123ae65e690fb855e045774.webp",980,1385]